Disease/Infection News

RSS

SpyCatcher-SpyTag technology used to develop recombinant protein-based intranasal vaccine against SARS-CoV-2

The findings of a new study showed that the intranasal SpyCage vaccine platform can be protective against SARS-CoV-2 and may prove to be a versatile and adaptable modality for the formulation of intranasal vaccines that target respiratory pathogens.

31 Oct 2022

The impact of genetic and lifestyle factors on the risk of major cardiovascular and thromboembolic events post-COVID-19 diagnosis

A new study aimed to analyze the association between lifestyle risk factors, PRSs, and their interactions along with the risk of CVE within 90 days post-COVID-19 diagnosis.

31 Oct 2022

An innovative nasal vaccine strategy to combat COVID

In a recent study published in the journal Science, researchers at Yale University developed a novel coronavirus disease 2019 (COVID-19) vaccination strategy termed 'prime and spike' (P&S) that leveraged existing systemic immunity triggered by parenteral vaccination (prime) to boost immunity at the respiratory mucosa.

31 Oct 2022

Effects of SARS-CoV-2-associated stress among pregnant women on development of fetus brain

Researchers in the United States evaluated the effects of maternal coronavirus disease 2019 (COVID-19) pandemic-associated stress and fetal brain development using magnetic resonance imaging (MRI).

30 Oct 2022

Psychosocial impact on pandemic workers in Shanghai during Omicron wave lockdown

In a recent study posted to the medRxiv* server, researchers assessed the well-being of all workers involved in coronavirus disease 2019 (COVID-19) testing between April and June 2022, i.e., during the Omicron wave lockdown in Shanghai, China.

30 Oct 2022

How COVID-19 impacted sleep and mental health among university students

In a recent study published in the journal PLoS ONE, researchers evaluated the effects of coronavirus disease 2019 (COVID-19) on the sleep quality and mental health (MH) of university-attending undergraduate students.

30 Oct 2022

New report on the impact of monkeypox on people with HIV

Researchers describe the presentation of patients severely infected with the monkeypox virus.

30 Oct 2022

SARS-CoV-2 infection can affect menstruation

Researchers assess the association between SARS-CoV-2 infection and menstrual irregularities.

30 Oct 2022

An estimated 15% of U.S. adults infected with SARS-CoV-2 have long-COVID

In a recent study published in the journal JAMA Network Open, researchers in the United States estimated the sociodemographic factors associated with and prevalence of post-acute coronavirus disease 2019 (COVID-19) symptom sequelae (PASC) or long COVID (LCOVID).

30 Oct 2022

An evaluation of the response to nationwide COVID-19 testing in England

Researchers in the Netherlands and the United Kingdom formulated recommendations for future pandemics using lessons learned from the testing programs implemented in the United Kingdom (UK) during the ongoing coronavirus disease 2019 (COVID-19) pandemic.

30 Oct 2022

Favorable outcomes of infants born after maternal COVID-19 during pregnancy

Researchers assess the outcomes of children born to mothers infected during pregnancy with SARS-CoV-2.

30 Oct 2022

Estimating the risk of airborne SARS-CoV-2 transmission in a train carriage

Researchers evaluate the risk of airborne transmission of SARS-CoV-2 in a mechanically ventilated inter-city train carriage.

30 Oct 2022

New insights on antibody response against SARS-CoV-2 Omiron sublineages

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research question.

28 Oct 2022

'What pediatricians need to know' about monkeypox in children

Children aged 8 years or younger should be considered a group at high risk for more severe monkeypox disease, reports The Pediatric Infectious Disease Journal, the official journal of The European Society for Paediatric Infectious Diseases.

28 Oct 2022

First anti-SARS Cov2 monoclonal antibody candidate of SpikImm demonstrates excellent tolerance

SPK001, the first anti-SARS Cov2 monoclonal antibody candidate of SpikImm, a French biotechnology company founded by Truffle Capital, originally discovered by the Institut Pasteur's Human Immunology Laboratory, directed by Dr. Hugo Mouquet (Inserm Joint Research Unit), has been tested on three initial cohorts of healthy volunteers, and has demonstrated excellent tolerance, in the context of the Phase 1 clinical study, recently labeled as a "national priority" by CAPNET (National Steering Committee for Therapeutic Trials and other Research on Covid-19).

28 Oct 2022

Study shows how Toxoplasma parasite successfully spreads in the body

The parasite Toxoplasma is carried by a large portion of the global human population. Now a study led by researchers at Stockholm University shows how this microscopic parasite so successfully spreads in the body, for example to the brain

28 Oct 2022

Researchers discover how hydroquinine inhibits major drug-resistant bacteria

Researchers say hydroquinine could be an effective weapon against a germ that can cause serious infections in humans, mostly hospital patients

28 Oct 2022

CU Anschutz study details the mechanisms behind the link between shingles and strokes

Scientists investigating why people who have had shingles are at a higher risk of stroke, now believe the answer lies within lipid vesicles called exosomes that shuttle proteins and genetic information between cells, according to new research from the University of Colorado Anschutz Medical Campus.

28 Oct 2022

Large listeriosis outbreak in Spain caused by contaminated stuffed pork

Listeria bacteria are ubiquitous in the environment and consumption of food contaminated with Listeria monocytogenes is one of the main routes for food-borne outbreaks.

28 Oct 2022

The impact of seasonal coronavirus immunity on susceptibility to SARS-CoV-2 infection and COVID-19 vaccination

Researchers investigated whether immunity against seasonal human coronavirus spike proteins of HKU1, OC43, NL63, or 229E could protect against SARS-CoV-2 in vitro.

28 Oct 2022